Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Eli Lilly announces mid-stage trial success for donanemab in Alzheimer’s

pharmatimesJanuary 14, 2021

Tag: Eli Lilly , donanemab , Alzheimer’s disease , TRAILBLAZER-ALZ

PharmaSources Customer Service